Specific gut or intratumoral microbiota (e.g., segmented filamentous bacteria) may modulate BC progression via the IL-17 pathway by promoting Th17 differentiation and increasing IL-17 secretion in mouse models [97]. Here, IL17A is linked to breast cancer.